The question behind the question
When someone writes "how do I get CAR-T in China", the question underneath is usually one of three things: can I even be treated, how long will it take, or what do I do first.
Those have different answers, and mixing them up is the single most common reason patients lose weeks. This is the operational guide — the sequence, the paperwork, the timing, the visa, the money — for a patient or family who has already decided to explore treatment in China and now wants to know what actually happens.

Seven gates, in order
CAR-T is not one appointment. It is a chain of gates, and each one can stop the process:
- Records review — someone qualified reads your pathology and treatment history
- Target confirmation — the antigen is still there, at sufficient density
- Eligibility — organ function, infection status, performance status
- Entry and arrival — visa, flights, accommodation
- On-site workup — imaging, cardiac, labs, final clearance
- Apheresis and manufacturing — collection, then two to three weeks of production
- Lymphodepletion, infusion and monitoring — the inpatient phase, then Day 30 and Day 90
The mistake is treating gate 4 as gate 1. Patients book flights first, arrive, and only then discover that their slides were never sent.
Gate 1: what to send before you ask anything
A Chinese centre cannot give you a real answer without these six things. Sending them properly is what separates a two-week start from a two-month one.
1. Pathology — the actual material, not just the report. The written report is not enough. The centre needs to re-stain and re-test, because eligibility for satri-cel depends on CLDN18.2 percentage and intensity, and eligibility for a CD19 product depends on confirmed CD19 expression.
2. The original pathology report, with the pathology number that matches the slides you send. Without matching numbers, most Chinese pathology departments will refuse the material.
3. Genomic and biomarker reports — NGS panels, HER2, MSI, PD-L1, TP53, MYC/BCL2 as applicable. For gastric cancer, HER2 negativity is part of the satri-cel label.
4. Imaging in original format — DICOM files or discs, not screenshots or PDF printouts. Staging and tumour burden cannot be assessed from a picture of a report.
5. A treatment history table you build yourself: each line of therapy, drug names, start and stop dates, best response, and reason for stopping. This is the single most useful document you can produce, and almost no patient arrives with it.
6. Current organ function and infection screen — full blood count, liver and renal panels, cardiac ejection fraction, and hepatitis B, hepatitis C, HIV, syphilis and tuberculosis screening. Some of these can be done at home; some will be repeated on arrival.
The pathology problem nobody warns you about
Human tissue is regulated as a special item at the border, in both directions, and hospitals do not hand over blocks casually.
Blocks are usually not lent out. Chinese hospitals retain paraffin blocks for 15 to 30 years because the tissue is irreplaceable — your tumour has already been removed, so the block cannot be re-made. What you can obtain is stained slides (H&E and immunohistochemistry) and white sections — unstained slices cut fresh from the block, which is how additional testing gets done elsewhere.
Carrying tissue across a border requires approval. For personal diagnosis and treatment purposes it is permitted, but the compliant route involves a special-item approval document from customs, applied for online, supported by an explanation of purpose, identity documents, the hospital's diagnosis certificate, the pathology sampling certificate, and the receiving hospital's acceptance letter.
Courier shipment of blocks is usually refused. Slides travel better than blocks, and they travel best in hand luggage with the original report, rather than in checked baggage that can be delayed or lost.
Ask the receiving hospital what it needs before you ask your own hospital to release anything. The number of white sections, the thickness, whether they need to be charged or adhesive-coated — getting this wrong wastes irreplaceable material and costs another trip to the pathology department.
What can be decided remotely — and what cannot
This distinction prevents most disappointment.
| Decided from records alone | Requires you to be in China |
|---|---|
| Whether the target is expressed | Final eligibility sign-off |
| Which product or trial fits | Organ function and cardiac clearance |
| Whether the line of therapy qualifies | Infection screening results |
| A provisional, itemised cost estimate | Actual bed and apheresis slot |
| Whether bridging therapy is likely needed | The infusion date itself |
A centre that promises a firm infusion date before seeing your slides is guessing. A centre that gives a written provisional assessment, with the caveats listed, is doing it properly.
Timeline, honestly
| Stage | Realistic duration |
|---|---|
| Records review and remote assessment | 3–10 days |
| Visa application | 2–4 weeks |
| Travel and arrival | 1–3 days |
| On-site workup and clearance | 3–7 days |
| Apheresis | 1 day |
| Manufacturing | 2–3 weeks |
| Bridging therapy, if needed | 2–4 weeks |
| Lymphodepletion | 3 days |
| Inpatient monitoring | 1–3 weeks |
| Discharge and Day 30 review | 4 weeks |
From first contact to infusion is realistically six to ten weeks, and the two largest variables are visa timing and whether bridging therapy is needed. Of that total, about four weeks is spent in China: roughly one week of workup and apheresis, then about three weeks covering lymphodepletion, infusion and inpatient monitoring. The remaining two to four weeks is the manufacturing window — if your team agrees and bridging therapy can be arranged locally, you can spend it at home, which splits the trip into two shorter stays instead of one long one. Anyone offering "come next week" has not accounted for manufacturing.
There is a specific trap here: arriving early does not shorten manufacturing, it only extends your hotel bill and your exposure to a hospital environment before your immune system has been rebuilt. Arrive when the workup can start, not before.
Choosing a centre
China has ten approved CAR-T products and, for satri-cel, 64 certified treatment centres. Certification matters, because the product is only released to centres that have met the manufacturer's training and handling requirements — and because complication management is what separates centres more than cure rates do.
Ask five questions, and expect written answers:
- How many CAR-T cases has this centre completed in the last 12 months?
- Does the centre have an intensive care unit on site, and how often are CAR-T patients admitted to it?
- Who handles grade 3 cytokine release syndrome at 3 a.m.?
- Is there a dedicated CAR-T ward, or are patients nursed in general haematology beds?
- Who is the named contact for international patients, and in what language?
Volume is the proxy that matters most. A centre doing a handful of cases a year is not the place to have your first complication.

The visa question, without the myths
There is no separate medical visa category in Chinese immigration law. What exists is the S2 short-term private-affairs visa, which in practice is the route used for medical treatment, supported by hospital documentation — a diagnosis certificate, an admission or appointment confirmation, and an invitation or acceptance letter from the treating hospital.
Three things catch families out:
Visa-free entry does not officially cover medical treatment. The unilateral visa-free arrangements for roughly 50 nationalities list business, tourism, family visits, exchange and transit as permitted purposes. Medical treatment is not on the list, and you cannot convert a visa-free entry into an S2 visa from inside China.
Hainan is the exception. The Hainan visa-free scheme explicitly includes medical treatment, but confines you to Hainan province. If your centre is in Shanghai, Beijing or Tianjin, that exception does not apply.
Companions need their own permission. There is no medical-companion visa. A spouse or adult child travelling with you must qualify in their own right, and documentation of the relationship may be required.
Rules change, vary by nationality, and are decided case by case by consular officers. Confirm your specific situation with the Chinese embassy or consulate in your country, or the national immigration hotline 12367, before booking anything non-refundable. Stay extensions are possible but discretionary, and must be applied for before your permitted stay expires.
Money mechanics
For international self-pay patients there is no insurance pathway. What matters is the cash flow order, because it tells you what you can still walk away from.
- Assessment and records review — usually free or a small fee
- Deposit — typically required before apheresis, not before
- Product payment — the largest instalment, due before or at infusion
- Ward, ICU and pharmacy — billed during the stay, itemised
- Follow-up — billed per visit
Ask specifically what happens if manufacturing fails, if the product does not meet release criteria, or if you become ineligible between apheresis and infusion. A written answer to those three questions is worth more than a discount.
For the full line-by-line cost picture, including why the Chinese total lands at a fraction of a US bill, see CAR-T cost in China vs the US.

Three mistakes that cost weeks
Arriving without the slides. The most common and most expensive. Pathology review cannot start, so the workup clock does not start either.
No bridging plan. If your disease is progressing while cells are manufactured, you may need chemotherapy in between. Centres that plan for this in advance lose less ground; centres that decide at the last minute often have to start over.
No handover for the return trip. Your home oncologist needs to manage cytopenias, immunoglobulin replacement and imaging for months. Some will take this on; some will not accept responsibility for a therapy they did not deliver. Settle it before you fly, in writing.
If you are turned down
Being rejected at gate 2 or 3 is common, and it is not the end of the road.
- Target not expressed, or expressed below threshold — ask whether a lower-threshold product, an antibody-drug conjugate, or a bispecific antibody fits instead
- Organ function or infection — some issues are treatable and re-testable in weeks
- Too advanced for licensed therapy — clinical trials are the realistic route, and China runs an unusually large number of them in this space
For what genuinely remains after a CAR-T course fails, including target switching and trial options, see what still works after CAR-T relapse.
The first 72 hours on arrival
Workup is fast but sequential, and knowing the order helps you push back on delays.
Day 1 is usually registration, blood work and cross-sectional imaging. Day 2 adds cardiac assessment and infectious disease review. Day 3 is where the treating team confirms eligibility and books apheresis. From apheresis to infusion, you are waiting on the laboratory, and there is nothing you can do to speed it up.
Use that waiting period deliberately: get the accommodation sorted, learn the hospital's after-hours route, and confirm who to call for fever.
If the patient is a child, read our guide to CAR-T for children with relapsed B-ALL in China first — the paediatric indication, the trial data and the bridge to transplant work differently from the adult pathway.
Getting started
The practical first move is not a flight and not a visa. It is a single package of documents — slides, original report, imaging in native format, a treatment-history table, and current labs — sent for review, so that eligibility and target expression are answered before any money is committed.
MedChinaGo's CAR-T programme reviews that package, confirms which approved product or trial fits, and returns a written assessment covering the likely timeline, the itemised cost and what still needs to be done on arrival. Learn more about CAR-T therapy in China, check which products are approved in China, read the satri-cel gastric cancer data, or compare CAR-T with transplant and chemotherapy if the treatment decision is still open.

